Your browser doesn't support javascript.
loading
Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
Aviki, Emeline M; Lavery, Jessica A; Roche, Kara Long; Cowan, Renee; Dessources, Kimberly; Basaran, Derman; Green, Angela K; Aghajanian, Carol A; O'Cearbhaill, Roisin; Jewell, Elizabeth L; Leitao, Mario M; Gardner, Ginger J; Abu-Rustum, Nadeem R; Sabbatini, Paul; Bach, Peter B.
Afiliação
  • Aviki EM; The Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America. Electronic addr
  • Lavery JA; The Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Roche KL; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Cowan R; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Dessources K; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Basaran D; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Green AK; The Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of Ameri
  • Aghajanian CA; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • O'Cearbhaill R; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Jewell EL; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Leitao MM; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Gardner GJ; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Abu-Rustum NR; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Sabbatini P; Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
  • Bach PB; The Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, United States of America.
Gynecol Oncol ; 159(2): 418-425, 2020 11.
Article em En | MEDLINE | ID: mdl-32814642
ABSTRACT

PURPOSE:

We sought to evaluate whether provider volume or other factors are associated with chemotherapy guideline compliance in elderly patients with epithelial ovarian cancer (EOC).

METHODS:

We queried the SEER-Medicare database for patients ≥66 years, diagnosed with FIGO stage II-IV EOC from 2004 to 2013 who underwent surgery and received chemotherapy within 7 months of diagnosis. We compared NCCN guideline compliance (6 cycles of platinum-based doublet) and chemotherapy-related toxicities across provider volume tertiles. Factors associated with guideline compliance and chemotherapy-related toxicities were assessed using logistic regression. Overall survival (OS) was compared across volume tertiles and Cox proportional-hazards model was created to adjust for case-mix.

RESULTS:

1924 patients met inclusion criteria. The overall rate of guideline compliance was 70.3% with a significant association between provider volume and compliance (64.5% for low-volume, 72.2% for medium-volume, 71.7% for high-volume, p = .02). In the multivariate model, treatment by low-volume providers and patient age ≥ 80 years were independently associated with worse chemotherapy-guideline compliance. In the survival analysis, there was a significant difference in median OS across provider volume tertiles with median survival of 32.8 months (95%CI 29.6, 36.4) low-volume, 41.9 months (95%CI 37.5, 46.7) medium-volume, 42.1 months (95%CI 38.8, 44.2) high-volume providers, respectively (p < .01). After adjusting for case-mix, low-volume providers were independently associated with higher rates of mortality (aHR 1.25, 95%CI 1.08, 1.43).

CONCLUSIONS:

In a modern cohort of elderly Medicare patients with advanced EOC, we found higher rates of non-compliant care and worse survival associated with treatment by low-volume Medicare providers. Urgent efforts are needed to address this volume-outcomes disparity.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fidelidade a Diretrizes / Hospitais com Alto Volume de Atendimentos / Hospitais com Baixo Volume de Atendimentos / Carcinoma Epitelial do Ovário Tipo de estudo: Guideline / Prognostic_studies Limite: Aged / Aged80 / Female / Humans País/Região como assunto: America do norte Idioma: En Revista: Gynecol Oncol Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Fidelidade a Diretrizes / Hospitais com Alto Volume de Atendimentos / Hospitais com Baixo Volume de Atendimentos / Carcinoma Epitelial do Ovário Tipo de estudo: Guideline / Prognostic_studies Limite: Aged / Aged80 / Female / Humans País/Região como assunto: America do norte Idioma: En Revista: Gynecol Oncol Ano de publicação: 2020 Tipo de documento: Article